Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 16/20 | 0.58 |
| ▸ | NPY1R | P25929 | 10/20 | 0.58 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.58 |
| ▸ | NPY2R | P49146 | 6/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30958046 | 1.00 | NPY4R (0.58) | NPY4RNPY1RNPY5RNPY2RALDH1A1 | |
| SCHEMBL29531992 | 1.00 | NPY4R (0.58) | NPY4RNPY1RNPY5RNPY2RALDH1A1 | |
| SCHEMBL3138301 | 1.00 | NPY4R (0.58) | NPY4RNPY1RNPY5RNPY2RALDH1A1 | |
| SCHEMBL29794924 | 1.00 | NPY4R (0.58) | NPY4RNPY1RNPY5RNPY2RALDH1A1 | |
| SCHEMBL29655324 | 0.97 | NPY4R (0.61) | NPY4RNPY1RNPY5RNPY2RALDH1A1 | |
| Acetic Acid SCHEMBL9189488 | 0.97 | NPY4R (0.56) | NPY4RNPY1RNPY5RNPY2RALDH1A1 | |
| Acetic Acid SCHEMBL9189505 | 0.97 | NPY4R (0.56) | NPY4RNPY1RNPY5RNPY2RALDH1A1 | |
| SCHEMBL29947104 | 0.97 | NPY4R (0.61) | NPY4RNPY1RNPY5RNPY2RALDH1A1 | |
| SCHEMBL27639946 | 0.97 | NPY4R (0.61) | NPY4RNPY1RNPY5RNPY2RALDH1A1 | |
| SCHEMBL31601685 | 0.96 | NPY4R (0.63) | NPY4RNPY1RNPY5RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 273 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4659591-A1 | TASTE-ENHANCING COMPOSITION, METHOD FOR PRODUCING SAME, FOOD PRODUCT, AND METHOD FOR ENHANCING TASTE OF FOOD PRODUCT | House Foods Group Inc. (JP) | 2025-12-10 | — | — | EP | claimed |
| EP-4659592-A1 | FLAVOR ENHANCING COMPOSITION, MANUFACTURING METHOD THEREFOR, AND METHOD FOR ENHANCING FLAVOR OF FOOD PRODUCT | House Foods Corporation (JP) | 2025-12-10 | — | — | EP | claimed |
| WO-2025002590-A1 | TISSUE MHC CLASS I IMMUNOPEPTIDE PATTERN DEDICATED FOR GENERATION OF ANTI-CANCER VACCINES AGAINST NON-SMALL CELL LUNG CANCER (NSCLC), IDENTIFICATION AND ISOLATION OF NSCLC SPECIFIC T CELLS IN HUMANS | UNIWERSYTET GDÁNSKI (PL) | 2025-01-02 | — | — | WO | claimed |
| EP-4472998-A1 | CYCLIC EPITOPE TAGS | BioNTech SE (DE) | 2024-12-11 | — | — | EP | claimed |
| US-20240315296-A1 | PEPTIDE COMPOUNDS FOR FLAVOR MODULATING | CJ CHEILJEDANG CORPORATION (KR) | 2024-09-26 | — | — | US | claimed |
| CN-118632859-A | Cyclic epitope tag | 生物技术欧洲股份公司 | 2024-09-10 | — | — | CN | claimed |
| WO-2024162422-A1 | TASTE-ENHANCING COMPOSITION, METHOD FOR PRODUCING SAME, FOOD PRODUCT, AND METHOD FOR ENHANCING TASTE OF FOOD PRODUCT | ハウス食品グループ本社株式会社 | 2024-08-08 | — | — | WO | claimed |
| WO-2024162421-A1 | FLAVOR ENHANCING COMPOSITION, MANUFACTURING METHOD THEREFOR, AND METHOD FOR ENHANCING FLAVOR OF FOOD PRODUCT | ハウス食品株式会社 | 2024-08-08 | — | — | WO | claimed |
| EP-4364582-A1 | PEPTIDE COMPOUNDS FOR FLAVOR MODULATING | CJ Cheiljedang Corporation (KR) | 2024-05-08 | — | — | EP | claimed |
| WO-2023148275-A1 | CYCLIC EPITOPE TAGS | BioNTech SE (DE) | 2023-08-10 | — | — | WO | claimed |
| CN-116411039-A | Preparation method, purification method and application of active peptide for inhibiting alpha-glucosidase | 桂林三金药业股份有限公司 | 2023-07-11 | — | — | CN | claimed |
| WO-2023277549-A1 | PEPTIDE COMPOUNDS FOR FLAVOR MODULATING | 씨제이제일제당 (주) | 2023-01-05 | — | — | WO | claimed |
| EP-3478121-A1 | METHOD FOR SAMPLING GINGIVAL METABOLITES | The Procter and Gamble Company (US) | 2019-05-08 | — | — | EP | claimed |
| CN-109414109-A | Method for sampling gums metabolin | 宝洁公司 | 2019-03-01 | — | — | CN | claimed |
| US-9964472-B2 | Methods for sampling gingival metabolites | THE PROCTER & GAMBLE COMPANY (US) | 2018-05-08 | — | — | US | claimed |
| US-20180003598-A1 | METHODS FOR SAMPLING GINGIVAL METABOLITES | THE PROCTER & GAMBLE COMPANY | 2018-01-04 | — | — | US | claimed |
| WO-2018005335-A1 | METHOD FOR SAMPLING GINGIVAL METABOLITES | THE PROCTER & GAMBLE COMPANY (US) | 2018-01-04 | — | — | WO | claimed |
| CN-106455664-A | Composition with high content of cyclic dipeptide | 三得利控股株式会社 | 2017-02-22 | — | — | CN | claimed |
| CN-106456633-A | Sugar metabolism improving agent | 三得利控股株式会社 | 2017-02-22 | — | — | CN | claimed |
| EP-4746919-A1 | AGENTS AND METHODS FOR TARGETED DELIVERY OF CYTOKINES TO IMMUNE CELLS | BioNTech SE (DE) | 2026-05-27 | — | — | EP | disclosed |
| EP-3931302-B1 | A GLUTATHIONE-RICH YEAST AND ITS USE FOR PRESERVING WINES | DANSTAR FERMENT AG (CH) | 2026-05-20 | — | — | EP | disclosed |
| US-20260132222-A1 | PROTEINS SPECIFIC FOR BAFF AND B7RP1 AND USES THEREOF | AMGEN INC. (US) | 2026-05-14 | — | — | US | disclosed |
| US-12622959-B2 | Coronavirus recombinant spike protein, polynucleotide encoding same, vector comprising polynucleotide, and vaccine for preventing or treating coronavirus infection, comprising vector | CELLID CO., LTD. (KR) | 2026-05-12 | — | — | US | disclosed |
| US-12600792-B2 | Monoclonal antibodies and methods of use | ELANCO TIERGESUNDHEIT AG (CH) | 2026-04-14 | — | — | US | disclosed |
| US-20260041769-A1 | AGENTS AND METHODS FOR TARGETED DELIVERY OF NUCLEIC ACIDS TO CELLS | BioNTech SE | 2026-02-12 | — | — | US | disclosed |
| US-12545746-B2 | Anti-BCMA car antibodies, conjugates, and methods of use | 2SEVENTY BIO, INC. (US) | 2026-02-10 | — | — | US | disclosed |
| US-20260035480-A1 | SICKLED BETA GLOBIN ANTIBODIES | BLUEBIRD BIO INC (US) | 2026-02-05 | — | — | US | disclosed |
| US-20260014278-A1 | HYBRID PEPTIDE DENDRIMER SYSTEMS AND EXTRAHEPATIC DELIVERY | NUNTIUS THERAPEUTICS LTD (GB) | 2026-01-15 | — | — | US | disclosed |
| WO-2025261607-A1 | PARTICLES, COMPOSITIONS AND METHODS | BioNTech SE (DE) | 2025-12-26 | — | — | WO | disclosed |
| US-20250384971-A1 | METHODS FOR CHARACTERISATION OF NANOCARRIERS | NUNTIUS THERAPEUTICS LTD (GB) | 2025-12-18 | — | — | US | disclosed |
| EP-4659591-A1 | TASTE-ENHANCING COMPOSITION, METHOD FOR PRODUCING SAME, FOOD PRODUCT, AND METHOD FOR ENHANCING TASTE OF FOOD PRODUCT | House Foods Group Inc. (JP) | 2025-12-10 | — | — | EP | disclosed |
| EP-4659592-A1 | FLAVOR ENHANCING COMPOSITION, MANUFACTURING METHOD THEREFOR, AND METHOD FOR ENHANCING FLAVOR OF FOOD PRODUCT | House Foods Corporation (JP) | 2025-12-10 | — | — | EP | disclosed |
| EP-4658250-A1 | COMPOSITIONS AND METHODS | BioNTech SE (DE) | 2025-12-10 | — | — | EP | disclosed |
| US-20250368956-A1 | TGFBETA SIGNAL CONVERTOR | REGENERON PHARMA (US) | 2025-12-04 | — | — | US | disclosed |
| US-12479930-B2 | Proteins specific for BAFF and B7RP1 and uses thereof | AMGEN INC. (US) | 2025-11-25 | — | — | US | disclosed |
| WO-2025228975-A1 | PARTICLES, COMPOSITIONS AND METHODS | BioNTech SE (DE) | 2025-11-06 | — | — | WO | disclosed |
| US-12454580-B2 | FRB antibodies | REGENERON PHARMACEUTICALS, INC. (US) | 2025-10-28 | — | — | US | disclosed |
| EP-3689371-B1 | PROTEINS SPECIFIC FOR BAFF AND B7RP1 AND USES THEREOF | AMGEN INC (US) | 2025-10-22 | — | — | EP | disclosed |
| US-12449424-B2 | In vitro method for detecting avian intestinal dysbiosis | EVONIK OPERATIONS GMBH (DE) | 2025-10-21 | — | — | US | disclosed |
| US-12441792-B2 | Antibodies specific for immunoglobulin-like transcript 3 (ILT3) and uses thereof | MERCK SHARP & DOHME LLC (US) | 2025-10-14 | — | — | US | disclosed |
| US-12435133-B2 | Antibodies specific for immunoglobulin-like transcript 3 (ILT3) and uses thereof | MERCK SHARP & DOHME LLC (US) | 2025-10-07 | — | — | US | disclosed |
| US-20250298041-A1 | NOVEL ASSAY FOR THE PLATELET BINDING ACTIVITY OF THE VON WILLEBRAND FACTOR | Li, Renhao (US) | 2025-09-25 | — | — | US | disclosed |
| US-20250289890-A1 | ANTI-CANCER COMBINATION THERAPIES COMPRISING CTLA-4 AND PD-1 BLOCKING AGENTS | MERCK SHARP & DOHME LLC (US) | 2025-09-18 | — | — | US | disclosed |
| US-20250257129-A9 | CD79A CHIMERIC ANTIGEN RECEPTORS | REGENERON PHARMA (US) | 2025-08-14 | — | — | US | disclosed |
| US-12365711-B2 | TGFβ signal convertor | REGENERON PHARMACEUTICALS, INC. (US) | 2025-07-22 | — | — | US | disclosed |
| US-12358986-B2 | Anti-cancer combination therapies comprising CTLA-4 and PD-1 blocking agents | MERCK SHARP & DOHME LLC (US) | 2025-07-15 | — | — | US | disclosed |
| US-12358989-B2 | HLA binding vaccine moieties and uses thereof | UNIVERSITY OF OSLO (NO) | 2025-07-15 | — | — | US | disclosed |
| EP-4581633-A1 | METHODS FOR CHARACTERISATION OF NANOCARRIERS | NUNTIUS THERAPEUTICS LIMITED (GB) | 2025-07-09 | — | — | EP | disclosed |
| US-20250197523-A1 | ANTI-BCMA CAR ANTIBODIES, CONJUGATES, AND METHODS OF USE | 2SEVENTY BIO, INC. | 2025-06-19 | — | — | US | disclosed |
| US-20250188154-A1 | CORONAVIRUS ANTIBODIES AND USES THEREOF | UNIV DUKE (US) | 2025-06-12 | — | — | US | disclosed |
| EP-4565279-A1 | HYBRID PEPTIDE DENDRIMER SYSTEMS AND EXTRAHEPATIC DELIVERY | NUNTIUS THERAPEUTICS LIMITED (GB) | 2025-06-11 | — | — | EP | disclosed |
| EP-4561584-A2 | SUSTAINED-RELEASE ORAL FOSAMPRENAVIR FORMULATION FOR TREATMENT OF REFLUX | The Medical College of Wisconsin, Inc. (US) | 2025-06-04 | — | — | EP | disclosed |
| CN-119997959-A | Sustained release oral fosamprenavir formulation for the treatment of reflux | 威斯康星州医药大学股份有限公司 | 2025-05-13 | — | — | CN | disclosed |
| WO-2025093665-A1 | PARTICLES, COMPOSITIONS AND METHODS | BioNTech SE (DE) | 2025-05-08 | — | — | WO | disclosed |
| CN-119947757-A | Hybrid peptide dendrimer systems and extrahepatic delivery | 信使治疗公司 | 2025-05-06 | — | — | CN | disclosed |
| CN-119930815-A | Fully human TSH receptor blocking monoclonal antibody, preparation and application thereof | 上海交通大学医学院附属第九人民医院 | 2025-05-06 | — | — | CN | disclosed |
| WO-2025078401-A1 | AGENTS AND METHODS FOR TARGETED DELIVERY OF IMMUNE EFFECTOR CELLS | BioNTech SE (DE) | 2025-04-17 | — | — | WO | disclosed |
| US-12268675-B2 | Diaryl substituted 6,5-fused ring compounds as C5aR inhibitors | CHEMOCENTRYX, INC. (US) | 2025-04-08 | — | — | US | disclosed |
| WO-2025072709-A2 | PHARMACOLOGICAL SUPPRESSION OF OTUD4 AND CD73 BINDING, METHODS OF TREATING CANCER, ANTICANCER AGENTS, AND THERAPEUTIC COMPOSITIONS | EMORY UNIVERSITY (US) | 2025-04-03 | — | — | WO | disclosed |
| EP-4530630-A2 | MONOCLONAL ANTIBODIES AND METHODS OF USE | Elanco Tiergesundheit AG (CH) | 2025-04-02 | — | — | EP | disclosed |
| US-20250082756-A1 | MUC16 CHIMERIC ANTIGEN RECEPTORS | REGENERON PHARMA (US) | 2025-03-13 | — | — | US | disclosed |
| US-12247084-B2 | Anti-BCMA CAR antibodies, conjugates, and methods of use | 2SEVENTY BIO, INC. (US) | 2025-03-11 | — | — | US | disclosed |
| US-12239630-B2 | Carboxylic acid aromatic amides as antagonists of bradykinin B1 receptor | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2025-03-04 | — | — | US | disclosed |
| US-12234296-B2 | Sickled beta globin antibodies | BLUEBIRD BIO, INC. (US) | 2025-02-25 | — | — | US | disclosed |
| CN-115068468-B | Carboxylic aromatic amides as bradykinin B1 receptor antagonists | 拜耳制药股份公司 | 2025-02-25 | — | — | CN | disclosed |
| CN-112368021-B | CD79A chimeric antigen receptor | 2赛文缇生物公司 | 2025-02-21 | — | — | CN | disclosed |
| US-20250051454-A1 | ANTIBODIES THAT TARGET HLA-E-HOST PEPTIDE COMPLEXES AND USES THEREOF | UNIV DUKE (US) | 2025-02-13 | — | — | US | disclosed |
| CN-112243381-B | Anti-BCMA CAR antibodies, conjugates, and methods of use | 2赛文缇生物公司 | 2025-02-07 | — | — | CN | disclosed |
| WO-2025027145-A1 | AGENTS AND METHODS FOR TARGETED DELIVERY TO CELLS | BioNTech SE (DE) | 2025-02-06 | — | — | WO | disclosed |
| WO-2025027182-A1 | AGENTS AND METHODS FOR TARGETED DELIVERY TO CELLS | BioNTech SE (DE) | 2025-02-06 | — | — | WO | disclosed |
| WO-2025027181-A1 | AGENTS AND METHODS FOR TARGETED DELIVERY TO CELLS | BioNTech SE (DE) | 2025-02-06 | — | — | WO | disclosed |
| WO-2025027077-A1 | AGENTS AND METHODS FOR TARGETED DELIVERY OF IMMUNE EFFECTOR CELLS | BioNTech SE (DE) | 2025-02-06 | — | — | WO | disclosed |
| WO-2025026553-A1 | AGENTS AND METHODS FOR TARGETED DELIVERY TO CELLS | BioNTech SE (DE) | 2025-02-06 | — | — | WO | disclosed |
| WO-2025021277-A1 | AGENTS AND METHODS FOR TARGETED DELIVERY OF CYTOKINES TO IMMUNE CELLS | BioNTech SE (DE) | 2025-01-30 | — | — | WO | disclosed |
| WO-2025021668-A1 | AGENTS AND METHODS FOR TARGETED DELIVERY OF CYTOKINES TO IMMUNE CELLS | BioNTech SE (DE) | 2025-01-30 | — | — | WO | disclosed |
| CN-118955625-B | Synthesis method of NH2-PEG4-RK (Dde) -OH | 南京恒远科技开发有限公司 | 2025-01-24 | — | — | CN | disclosed |
| US-20250026828-A1 | CD79A CHIMERIC ANTIGEN RECEPTORS | REGENERON PHARMA (US) | 2025-01-23 | — | — | US | disclosed |
| US-20250019443-A1 | ANTIBODIES THAT TARGET HLA-E-HOST PEPTIDE COMPLEXES AND USES THEREOF | UNIV DUKE (US) | 2025-01-16 | — | — | US | disclosed |
| US-20250009841-A1 | Methods of Diagnosing and Managing Bleeding Disorders | UNIV EMORY (US) | 2025-01-09 | — | — | US | disclosed |
| CN-114206936-B | Compositions and methods for treating cancer | 2赛文缇生物公司 | 2025-01-03 | — | — | CN | disclosed |
| WO-2025002590-A1 | TISSUE MHC CLASS I IMMUNOPEPTIDE PATTERN DEDICATED FOR GENERATION OF ANTI-CANCER VACCINES AGAINST NON-SMALL CELL LUNG CANCER (NSCLC), IDENTIFICATION AND ISOLATION OF NSCLC SPECIFIC T CELLS IN HUMANS | UNIWERSYTET GDÁNSKI (PL) | 2025-01-02 | — | — | WO | disclosed |
| CN-111788185-B | Diaryl substituted 6,5 fused ring compounds as C5a inhibitors | 凯莫森特里克斯股份有限公司 | 2024-12-13 | — | — | CN | disclosed |
| US-20240409666-A1 | Polypeptides That Bind to von Willebrand Factor (VWF) A1 Domain or an Autoinhibitory Module, Variants, and Uses Thereof | LI RENHAO (US) | 2024-12-12 | — | — | US | disclosed |
| EP-4472672-A1 | AGENTS AND METHODS FOR TARGETED DELIVERY TO CELLS | BioNTech SE (DE) | 2024-12-11 | — | — | EP | disclosed |
| EP-4472673-A1 | AGENTS AND METHODS FOR TARGETED DELIVERY OF NUCLEIC ACIDS TO CELLS | BioNTech SE (DE) | 2024-12-11 | — | — | EP | disclosed |
| EP-4472998-A1 | CYCLIC EPITOPE TAGS | BioNTech SE (DE) | 2024-12-11 | — | — | EP | disclosed |
| CN-119074891-A | Application of apoptosis element combined peptide in preparation of medicament for treating epilepsy | 哈尔滨医科大学 | 2024-12-06 | — | — | CN | disclosed |
| US-12152182-B2 | Polymer nanoparticles for afterglow molecular imaging | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2024-11-26 | — | — | US | disclosed |
| EP-4463471-A2 | MUC16 CHIMERIC ANTIGEN RECEPTORS | Regeneron Pharmaceuticals, Inc. (US) | 2024-11-20 | — | — | EP | disclosed |
| CN-118955625-A | Synthesis method of NH2-PEG4-RK (Dde) -OH | 南京恒远科技开发有限公司 | 2024-11-15 | — | — | CN | disclosed |
| CN-111100197-B | Factor 1 proteins, factor 2 proteins and inhibitors thereof for the treatment or prophylaxis of diseases | 汉诺威医学院 | 2024-11-15 | — | — | CN | disclosed |
| CN-118973618-A | Agents and methods for targeted delivery of nucleic acids to cells | 生物技术欧洲股份公司 | 2024-11-15 | — | — | CN | disclosed |
| CN-118973619-A | Agents and methods for targeted delivery to cells | 生物技术欧洲股份公司 | 2024-11-15 | — | — | CN | disclosed |
| US-20240368619-A1 | METHODS AND COMPOSITIONS FOR PPO HERBICIDE TOLERANCE | DLF SEEDS (DK) | 2024-11-07 | — | — | US | disclosed |
| US-20240368276-A1 | SALVAGE CHIMERIC ANTIGEN RECEPTOR SYSTEMS | REGENERON PHARMACEUTICALS, INC. | 2024-11-07 | — | — | US | disclosed |
| CN-118813570-A | Flavone glycosyltransferase, mutant and application thereof | 井冈山大学 | 2024-10-22 | — | — | CN | disclosed |
| CN-118829652-A | MUC16 chimeric antigen receptor | 再生元制药公司 | 2024-10-22 | — | — | CN | disclosed |
| US-20240342215-A1 | ENGINEERED T CELL RECEPTORS FUSED TO BINDING DOMAINS FROM ANTIBODIES | REGENERON PHARMACEUTICALS, INC. | 2024-10-17 | — | — | US | disclosed |
| EP-3773563-B1 | PRODRUGS OF FUSED-BICYCLIC C5AR ANTAGONISTS | CHEMOCENTRYX INC (US) | 2024-10-16 | — | — | EP | disclosed |
| US-20240315296-A1 | PEPTIDE COMPOUNDS FOR FLAVOR MODULATING | CJ CHEILJEDANG CORPORATION (KR) | 2024-09-26 | — | — | US | disclosed |
| CN-110922468-B | Factor 1 proteins, factor 2 proteins and inhibitors thereof for the treatment or prophylaxis of diseases | 汉诺威医学院 | 2024-09-24 | — | — | CN | disclosed |
| CN-118632859-A | Cyclic epitope tag | 生物技术欧洲股份公司 | 2024-09-10 | — | — | CN | disclosed |
| CN-110437336-B | Proteins specific for BAFF and B7RP1 and uses thereof | 美国安进公司 | 2024-08-27 | — | — | CN | disclosed |
| CN-118496381-A | Chimeric antigen receptor polypeptide, nucleic acid, vector, lentivirus for simultaneously expressing mbIL-15 cytokine and CXCR5 chemokine receptor and application | 天津市第一中心医院 | 2024-08-16 | — | — | CN | disclosed |
| CN-115137726-B | Carboxylic aromatic amides as bradykinin B1 receptor antagonists | 拜耳制药股份公司 | 2024-08-13 | — | — | CN | disclosed |
| US-12060419-B2 | CD79A chimeric antigen receptors | REGENERON PHARMACEUTICALS, INC. (US) | 2024-08-13 | — | — | US | disclosed |
| WO-2024162421-A1 | FLAVOR ENHANCING COMPOSITION, MANUFACTURING METHOD THEREFOR, AND METHOD FOR ENHANCING FLAVOR OF FOOD PRODUCT | ハウス食品株式会社 | 2024-08-08 | — | — | WO | disclosed |
| WO-2024160829-A1 | COMPOSITIONS AND METHODS | BioNTech SE (DE) | 2024-08-08 | — | — | WO | disclosed |
| WO-2024162422-A1 | TASTE-ENHANCING COMPOSITION, METHOD FOR PRODUCING SAME, FOOD PRODUCT, AND METHOD FOR ENHANCING TASTE OF FOOD PRODUCT | ハウス食品グループ本社株式会社 | 2024-08-08 | — | — | WO | disclosed |
| US-20240228624-A9 | HLA BINDING VACCINE MOIETIES AND USES THEREOF | UNIV OSLO (NO) | 2024-07-11 | — | — | US | disclosed |
| US-12023319-B2 | Carboxylic acid aromatic amides | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2024-07-02 | — | — | US | disclosed |
| WO-2024132726-A1 | SERUM PEPTIDE PATTERNS FOR DIAGNOSTICS OF ACUTE ISCHEMIC STROKE IN HUMANS AND DIFFERENTIAL DIAGNOSIS OF ACUTE ISCHEMIC STROKE FROM INTRACRANIAL HEMORRHAGIC STROKE | UNIWERSYTET GDANSKI (PL) | 2024-06-27 | — | — | WO | disclosed |
| US-20240191276-A1 | METHODS FOR LIGATION OF (POLY)PEPTIDES AND OLIGONUCLEOTIDES | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2024-06-13 | — | — | US | disclosed |
| CN-113167803-B | In-vitro detection method for intestinal dysbiosis of poultry | 赢创运营有限公司 | 2024-06-07 | — | — | CN | disclosed |
| EP-4365194-A2 | CD79A CHIMERIC ANTIGEN RECEPTORS | 2seventy bio, Inc. (US) | 2024-05-08 | — | — | EP | disclosed |
| EP-4364582-A1 | PEPTIDE COMPOUNDS FOR FLAVOR MODULATING | CJ Cheiljedang Corporation (KR) | 2024-05-08 | — | — | EP | disclosed |
| US-11976116-B2 | Salvage chimeric antigen receptor systems | 2SEVENTY BIO, INC. (US) | 2024-05-07 | — | — | US | disclosed |
| CN-117980326-A | Engineered T cell receptors fused to binding domains from antibodies | 2赛文缇生物公司 | 2024-05-03 | — | — | CN | disclosed |
| CN-117940585-A | Methods for identifying responsiveness to fibroblast growth factor receptor 1 inhibitor therapy | 科隆大学 | 2024-04-26 | — | — | CN | disclosed |
| US-20240132596-A1 | HLA BINDING VACCINE MOIETIES AND USES THEREOF | Nykode Therapeutics ASA (NO) | 2024-04-25 | — | — | US | disclosed |
| US-20240124579-A1 | KIR3DL2 BINDING AGENTS | INNATE PHARMA (FR) | 2024-04-18 | — | — | US | disclosed |
| EP-4353822-A2 | TGF BETA SIGNAL CONVERTOR | 2seventy bio, Inc. (US) | 2024-04-17 | — | — | EP | disclosed |
| US-20240108040-A1 | HIGH INTENSITY SWEETENERS | FIRMENICH INCORPORATED (US) | 2024-04-04 | — | — | US | disclosed |
| US-20240108753-A1 | NUCLEIC ACID DELIVERY | NUNTIUS THERAPEUTICS LIMITED (GB) | 2024-04-04 | — | — | US | disclosed |
| CN-117796397-A | Application of L-amino acid as bacillus thuringiensis pesticide synergist | 福建农林大学 | 2024-04-02 | — | — | CN | disclosed |
| CN-117720665-A | TGF beta signal converter | 2赛文缇生物公司 | 2024-03-19 | — | — | CN | disclosed |
| EP-3728203-B1 | DIARYL SUBSTITUTED 6,5-FUSED RING COMPOUNDS AS C5aR INHIBITORS | CHEMOCENTRYX INC (US) | 2024-03-13 | — | — | EP | disclosed |
| WO-2024047246-A1 | METHODS FOR CHARACTERISATION OF NANOCARRIERS | NUNTIUS THERAPEUTICS LIMITED (GB) | 2024-03-07 | — | — | WO | disclosed |
| EP-2945642-B1 | FACTOR 1 PROTEIN FOR USE IN TREATING OR PREVENTING DISEASES | MEDIZINISCHE HOCHSCHULE HANNOVER (DE) | 2024-02-21 | — | — | EP | disclosed |
| US-11905270-B2 | Carboxylic acid aromatic amides as antagonists of bradykinin B1 receptor | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2024-02-20 | — | — | US | disclosed |
| EP-3806903-B1 | CD79A CHIMERIC ANTIGEN RECEPTORS | 2SEVENTY BIO INC (US) | 2024-02-14 | — | — | EP | disclosed |
| CN-117545850-A | Method for ligating polypeptide and oligonucleotide | 南洋理工大学 | 2024-02-09 | — | — | CN | disclosed |
| WO-2024028465-A1 | HYBRID PEPTIDE DENDRIMER SYSTEMS AND EXTRAHEPATIC DELIVERY | NUNTIUS THERAPEUTICS LIMITED (GB) | 2024-02-08 | — | — | WO | disclosed |
| US-20240041764-A1 | Sustained-Release Oral Fosamprenavir Formulation for Treatment of Reflux | N-ZYME BIOMEDICAL INC. (CA) | 2024-02-08 | — | — | US | disclosed |
| WO-2024023583-A2 | SUSTAINED-RELEASE ORAL FOSAMPRENAVIR FORMULATION FOR TREATMENT OF REFLUX | THE MEDICAL COLLEGE OF WISCONSIN, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| CN-117460537-A | Nucleic acid delivery | 信使治疗公司 | 2024-01-26 | — | — | CN | disclosed |
| EP-3541833-B1 | TGF BETA SIGNAL CONVERTOR | 2SEVENTY BIO INC (US) | 2024-01-24 | — | — | EP | disclosed |
| CN-117402256-A | Protein dimers consisting of GLP-1 and EGF (A) analogues | 乐普（北京）医疗器械股份有限公司 | 2024-01-16 | — | — | CN | disclosed |
| WO-2024006975-A1 | METHODS FOR ANTIBODY HUMANIZATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-01-04 | — | — | WO | disclosed |
| EP-4298231-A1 | METHODS FOR LIGATION OF (POLY)PEPTIDES AND OLIGONUCLEOTIDES | Nanyang Technological University (SG) | 2024-01-03 | — | — | EP | disclosed |
| US-11858990-B2 | KIR3DL2 binding agents | INNATE PHARMA (FR) | 2024-01-02 | — | — | US | disclosed |
| CN-111954525-B | Prodrugs of fused bicyclic C5aR antagonists | 凯莫森特里克斯股份有限公司 | 2023-12-26 | — | — | CN | disclosed |
| CN-111788184-B | Diaryl substituted 5, 5-fused ring compounds useful as C5aR inhibitors | 凯莫森特里克斯股份有限公司 | 2023-12-22 | — | — | CN | disclosed |
| US-11845729-B2 | Processes and intermediates in the preparation of C5aR antagonists | CHEMOCENTRYX, INC. (US) | 2023-12-19 | — | — | US | disclosed |
| CN-110072885-B | TGF beta signal converter | 2赛文缇生物公司 | 2023-12-19 | — | — | CN | disclosed |
| CN-115073421-B | Carboxylic aromatic amides as bradykinin B1 receptor antagonists | 拜耳制药股份公司 | 2023-12-19 | — | — | CN | disclosed |
| EP-4284438-A1 | NUCLEIC ACID DELIVERY | NUNTIUS THERAPEUTICS LIMITED (GB) | 2023-12-06 | — | — | EP | disclosed |
| US-20230364141-A1 | TGFBETA SIGNAL CONVERTOR | REGENERON PHARMACEUTICALS, INC. | 2023-11-16 | — | — | US | disclosed |
| US-11807609-B2 | Deuterated compounds as immunomodulators | CHEMOCENTRYX, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-11780924-B2 | HLA binding vaccine moieties and uses thereof | UNIVERSITY OF OSLO (NO) | 2023-10-10 | — | — | US | disclosed |
| US-20230310604-A1 | BCMA CHIMERIC ANTIGEN RECEPTORS | 2SEVENTY BIO, INC. (US) | 2023-10-05 | — | — | US | disclosed |
| EP-2970477-B1 | BISPECIFIC-FC MOLECULES | AMGEN INC (US) | 2023-10-04 | — | — | EP | disclosed |
| US-11773091-B2 | 6-5 fused rings as C5a inhibitors | CHEMOCENTRYX, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-11758933-B2 | High intensity sweeteners | FIRMENICH INCORPORATED (US) | 2023-09-19 | — | — | US | disclosed |
| US-11753475-B2 | Bispecific-Fc molecules | AMGEN INC. (US) | 2023-09-12 | — | — | US | disclosed |
| CN-116716324-A | Alkane degradation gene, protein and application thereof | 山东省科学院生态研究所(山东省科学院中日友好生物技术研究中心) | 2023-09-08 | — | — | CN | disclosed |
| US-20230279145-A1 | SICKLED BETA GLOBIN ANTIBODIES | GENETIX BIOTHERAPEUTICS INC. | 2023-09-07 | — | — | US | disclosed |
| US-20230271931-A1 | CARBOXYLIC ACID AROMATIC AMIDES AS ANTAGONISTS OF BRADYKININ B1 RECEPTOR | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2023-08-31 | — | — | US | disclosed |
| CN-116621931-A | Actinomycete cyclic lipopeptid compound and extraction method and application thereof | 上海交通大学医学院附属仁济医院 | 2023-08-22 | — | — | CN | disclosed |
| WO-2023148275-A1 | CYCLIC EPITOPE TAGS | BioNTech SE (DE) | 2023-08-10 | — | — | WO | disclosed |
| WO-2023148277-A1 | AGENTS AND METHODS FOR TARGETED DELIVERY OF NUCLEIC ACIDS TO CELLS | BioNTech SE (DE) | 2023-08-10 | — | — | WO | disclosed |
| WO-2023148276-A1 | AGENTS AND METHODS FOR TARGETED DELIVERY TO CELLS | BioNTech SE (DE) | 2023-08-10 | — | — | WO | disclosed |
| CN-116496962-A | Pseudo uridine engineering bacterium, application thereof and method for producing pseudo uridine | 台州学院 | 2023-07-28 | — | — | CN | disclosed |
| WO-2023133358-A2 | MUC16 CHIMERIC ANTIGEN RECEPTORS | 2SEVENTY BIO, INC. (US) | 2023-07-13 | — | — | WO | disclosed |
| CN-116411039-A | Preparation method, purification method and application of active peptide for inhibiting alpha-glucosidase | 桂林三金药业股份有限公司 | 2023-07-11 | — | — | CN | disclosed |
| US-20230212297-A1 | BISPECIFIC FC MOLECULES | AMGEN INC. | 2023-07-06 | — | — | US | disclosed |
| US-20230212318-A1 | PROTEASE-ACTIVATABLE BISPECIFIC PROTEINS | AMGEN INC. | 2023-07-06 | — | — | US | disclosed |
| EP-4204457-A2 | BCMA CHIMERIC ANTIGEN RECEPTORS | 2seventy bio, Inc. (US) | 2023-07-05 | — | — | EP | disclosed |
| WO-2023122211-A2 | CORONAVIRUS ANTIBODIES AND USES THEREOF | DUKE UNIVERSITY (US) | 2023-06-29 | — | — | WO | disclosed |
| CN-116348496-A | BCMA chimeric antigen receptor | 2赛文缇生物公司 | 2023-06-27 | — | — | CN | disclosed |
| US-20230190930-A1 | ANTI-NUCLEOLIN ANTIBODIES | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2023-06-22 | — | — | US | disclosed |
| WO-2023108095-A1 | POLYPEPTIDES THAT BIND TO VON WILLEBRAND FACTOR (VWF) AL DOMAIN OR AN AUTOINHIBITORY MODULE, VARIANTS, AND USES THEREOF | EMORY UNIVERSITY (US) | 2023-06-15 | — | — | WO | disclosed |
| WO-2023108101-A1 | ANTIBODIES THAT INHIBIT GLYCOPROTEIN IB-IX MEDIATED PLATELET SIGNALING AND USES IN MANAGING BLEEDING CONDITIONS | EMORY UNIVERSITY (US) | 2023-06-15 | — | — | WO | disclosed |
| US-11654158-B2 | TGFBeta signal convertor | 2SEVENTY BIO, INC. (US) | 2023-05-23 | — | — | US | disclosed |
| US-20230151002-A1 | 6-5 FUSED RINGS AS C5a INHIBITORS | CHEMOCENTRYX, INC. | 2023-05-18 | — | — | US | disclosed |
| US-20230151117-A1 | FRB ANTIBODIES | 2SEVENTY BIO, INC. (US) | 2023-05-18 | — | — | US | disclosed |
| US-11643651-B2 | Compositions and methods for protein production | SYNGENTA PARTICIPATIONS AG (CH) | 2023-05-09 | — | — | US | disclosed |
| CN-116033916-A | Aerosol formulations of HIV protease inhibitors for the treatment of airway reflux | 威斯康星州医药大学股份有限公司 | 2023-04-28 | — | — | CN | disclosed |
| US-20230128444-A1 | PROTEINS SPECIFIC FOR BAFF AND B7RP1 AND USES THEREOF | AMGEN INC. (US) | 2023-04-27 | — | — | US | disclosed |
| US-11634502-B2 | Heterodimeric bispecific antibodies | AMGEN INC. (US) | 2023-04-25 | — | — | US | disclosed |
| US-20230124937-A1 | A Glutathione-Rich Yeast and Its Use for Preserving Wines | UNIVERSITE DE BOURGOGNE (FR) | 2023-04-20 | — | — | US | disclosed |
| US-20230112863-A1 | IL-1 Binding Proteins | ABBVIE INC (US) | 2023-04-13 | — | — | US | disclosed |
| US-20230115912-A1 | DIARYL SUBSTITUTED 6,5-FUSED RING COMPOUNDS AS C5aR INHIBITORS | CHEMOCENTRYX, INC. | 2023-04-13 | — | — | US | disclosed |
| US-20230102258-A1 | C5AR ANTAGONISTS | CHEMOCENTRYX, INC. | 2023-03-30 | — | — | US | disclosed |
| US-20230086179-A1 | CARBOXYLIC ACID AROMATIC AMIDES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2023-03-23 | — | — | US | disclosed |
| US-11608336-B2 | Prodrugs of fused-bicyclic C5aR antagonists | CHEMOCENTRYX, INC. (US) | 2023-03-21 | — | — | US | disclosed |
| US-20230077648-A1 | Heterodimeric Bispecific Antibodies | AMGEN INC. | 2023-03-16 | — | — | US | disclosed |
| US-20230078695-A1 | Aerosolized Formulations of HIV Protease Inhibitors for the Treatment of Airway Reflux | THE MEDICAL COLLEGE OF WISCONSIN, INC. | 2023-03-16 | — | — | US | disclosed |
| US-20230055407-A1 | V-C-FC-V-C ANTIBODY | AMGEN INC. | 2023-02-23 | — | — | US | disclosed |
| EP-4135740-A1 | AEROSOLIZED FORMULATIONS OF HIV PROTEASE INHIBITORS FOR THE TREATMENT OF AIRWAY REFLUX | The Medical College of Wisconsin, Inc. (US) | 2023-02-22 | — | — | EP | disclosed |
| CN-108137669-B | anti-ROR 1 chimeric antigen receptor | 优瑞科生物技术公司 | 2023-02-17 | — | — | CN | disclosed |
| US-20230043209-A1 | CARBOXYLIC ACID AROMATIC AMIDES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2023-02-09 | — | — | US | disclosed |
| US-20230030085-A1 | ANTI-BCMA CAR ANTIBODIES, CONJUGATES, AND METHODS OF USE | 2SEVENTY BIO, INC. (US) | 2023-02-02 | — | — | US | disclosed |
| US-20230008966-A1 | PROCESSES AND INTERMEDIATES IN THE PREPARATION OF C5aR ANTAGONISTS | CHEMOCENTRYX, INC. | 2023-01-12 | — | — | US | disclosed |
| WO-2023277549-A1 | PEPTIDE COMPOUNDS FOR FLAVOR MODULATING | 씨제이제일제당 (주) | 2023-01-05 | — | — | WO | disclosed |
| US-20220411507-A1 | ANTI-CANCER COMBINATION THERAPIES COMPRISING CTLA-4 AND PD-1 BLOCKING AGENTS | MERCK SHARP & DOHME CORP. (US) | 2022-12-29 | — | — | US | disclosed |
| US-11535681-B2 | Sickled beta globin antibodies | BLUEBIRD BIO, INC. (US) | 2022-12-27 | — | — | US | disclosed |
| CN-110997674-B | 6-5 fused rings as C5a inhibitors | 凯莫森特里克斯股份有限公司 | 2022-12-20 | — | — | CN | disclosed |
| CN-111032658-B | 5-5 fused rings as C5a inhibitors | 凯莫森特里克斯股份有限公司 | 2022-12-20 | — | — | CN | disclosed |
| EP-3630775-B1 | 6-5 FUSED RINGS AS C5a INHIBITORS | CHEMOCENTRYX INC (US) | 2022-12-14 | — | — | EP | disclosed |
| CN-115397864-A | Modified CCR polypeptides and uses thereof | 2赛文缇生物公司 | 2022-11-25 | — | — | CN | disclosed |
| EP-3894863-B1 | IN VITRO METHOD FOR DETECTING AVIAN INTESTINAL DYSBIOSIS | EVONIK OPERATIONS GMBH (DE) | 2022-11-23 | — | — | EP | disclosed |
| EP-3630774-B1 | 5-5 FUSED RINGS AS C5A INHIBITORS | CHEMOCENTRYX INC (US) | 2022-11-23 | — | — | EP | disclosed |
| US-11492417-B2 | Proteins specific for BAFF and B7RP1 and uses thereof | AMGEN INC. (US) | 2022-11-08 | — | — | US | disclosed |
| US-11485737-B2 | Diaryl substituted 5,5-fused ring compounds as C5aR inhibitors | CHEMOCENTRYX, INC. (US) | 2022-11-01 | — | — | US | disclosed |
| US-20220340644-A1 | INFLUENZA NEUTRALIZING ANTIBODIES AND THEIR USES | DUKE UNIVERSITY | 2022-10-27 | — | — | US | disclosed |
| EP-4076522-A1 | ANTI-BCMA CAR ANTIBODIES, CONJUGATES, AND METHODS OF USE | 2seventy bio, Inc. (US) | 2022-10-26 | — | — | EP | disclosed |
| US-11478460-B2 | Diaryl substituted 6,5-fused ring compounds as C5aR inhibitors | CHEMOCENTRYX, INC. (US) | 2022-10-25 | — | — | US | disclosed |
| US-11479553-B2 | 5-5 fused rings as C5a inhibitors | CHEMOCENTRYX, INC. (US) | 2022-10-25 | — | — | US | disclosed |
| WO-2022162200-A9 | Nucleic Acid Delivery | Nuntius Therapeutics Ltd. (GB) | 2022-10-13 | — | — | WO | disclosed |
| CN-115137726-A | Carboxylic acid aromatic amides as bradykinin B1 receptor antagonists | 拜耳制药股份公司 | 2022-10-04 | — | — | CN | disclosed |
| EP-2970484-B2 | HETERODIMERIC BISPECIFIC ANTIBODIES | AMGEN INC (US) | 2022-09-21 | — | — | EP | disclosed |
| CN-115068468-A | Carboxylic aromatic amides as bradykinin B1 receptor antagonists | 拜耳制药股份公司 | 2022-09-20 | — | — | CN | disclosed |
| CN-115073421-A | Carboxylic acid aromatic amides as bradykinin B1 receptor antagonists | 拜耳制药股份公司 | 2022-09-20 | — | — | CN | disclosed |
| US-20220280567-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | 2SEVENTY BIO, INC. (US) | 2022-09-08 | — | — | US | disclosed |
| WO-2022182294-A1 | METHODS FOR LIGATION OF (POLY)PEPTIDES AND OLIGONUCLEOTIDES | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2022-09-01 | — | — | WO | disclosed |
| CN-114929277-A | anti-BCMA CAR antibodies, conjugates, and methods of use | 2赛文缇生物公司 | 2022-08-19 | — | — | CN | disclosed |
| US-20220251230-A1 | MONOCLONAL ANTIBODIES AND METHODS OF USE | ELANCO TIERGESUNDHEIT AG (CH) | 2022-08-11 | — | — | US | disclosed |
| WO-2022162200-A1 | Nucleic Acid Delivery | Nuntius Therapeutics Ltd. (GB) | 2022-08-04 | — | — | WO | disclosed |
| EP-3682879-B1 | PROCESSES AND INTERMEDIATES IN THE PREPARATION OF C5AR ANTAGONISTS | CHEMOCENTRYX INC (US) | 2022-08-03 | — | — | EP | disclosed |
| CN-110325523-B | Carboxylic acid aromatic amides as bradykinin B1 receptor antagonists | 拜耳制药股份公司 | 2022-07-26 | — | — | CN | disclosed |
| US-20220226374-A1 | CD79B CHIMERIC ANTIGEN RECEPTORS | 2seventy bio, Inc (US) | 2022-07-21 | — | — | US | disclosed |
| US-20220218745-A1 | MULTIVALENT CHIMERIC ANTIGEN RECEPTOR | 2SEVENTY BIO, INC. (US) | 2022-07-14 | — | — | US | disclosed |
| US-11384079-B2 | 6-5 fused rings as C5a inhibitors | CHEMOCENTRYX, INC. (US) | 2022-07-12 | — | — | US | disclosed |
| US-20220195529-A1 | ISOFORMS OF GATA6 AND NKX2-1 AS MARKERS FOR DIAGNOSIS AND THERAPY OF CANCER AND AS TARGETS FOR ANTI-CANCER THERAPY | MAX PLANCK GESELLSCHAFT (DE) | 2022-06-23 | — | — | US | disclosed |
| US-20220195039-A1 | SALVAGE CHIMERIC ANTIGEN RECEPTOR SYSTEMS | 2SEVENTY BIO, INC. (US) | 2022-06-23 | — | — | US | disclosed |
| EP-4014996-A1 | ANTI-SIALYL TN CHIMERIC ANTIGEN RECEPTORS | Helixmith Co., Ltd (KR) | 2022-06-22 | — | — | EP | disclosed |
| EP-4015504-A1 | C5AR ANTAGONISTS | ChemoCentryx, Inc. (US) | 2022-06-22 | — | — | EP | disclosed |
| EP-3368542-B1 | HIGH INTENSITY SWEETENERS | FIRMENICH INCORPORATED (US) | 2022-06-22 | — | — | EP | disclosed |
| US-11357246-B2 | High intensity sweeteners | FIRMENICH INCORPORATED (US) | 2022-06-14 | — | — | US | disclosed |
| US-11357849-B2 | Anti-nucleolin antibodies | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2022-06-14 | — | — | US | disclosed |
| EP-3456344-B1 | PROTEINS SPECIFIC FOR BAFF AND B7RP1 AND USES THEREOF | AMGEN INC (US) | 2022-05-04 | — | — | EP | disclosed |
| US-11319377-B2 | Monoclonal antibodies and methods of use | ELANCO TIERGESUNDHEIT AG (CH) | 2022-05-03 | — | — | US | disclosed |
| US-11312974-B2 | Gene for increasing plant biomass and use therefor | KANEKA CORPORATION (JP) | 2022-04-26 | — | — | US | disclosed |
| EP-3983445-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | 2seventy bio, Inc. (US) | 2022-04-20 | — | — | EP | disclosed |
| US-11279769-B2 | Anti-Sialyl Tn chimeric antigen receptors | HELIXMITH CO., LTD (KR) | 2022-03-22 | — | — | US | disclosed |
| CN-114206936-A | Compositions and methods for treating cancer | 2赛文缇生物公司 | 2022-03-18 | — | — | CN | disclosed |
| WO-2022046730-A2 | BCMA CHIMERIC ANTIGEN RECEPTORS | BLUEBIRD BIO, INC. (US) | 2022-03-03 | — | — | WO | disclosed |
| US-20220050115-A1 | IN VITRO METHOD FOR DETECTING AVIAN INTESTINAL DYSBIOSIS | EVONIK OPERATIONS GMBH (DE) | 2022-02-17 | — | — | US | disclosed |
| US-20220034902-A1 | METHOD FOR IDENTIFYING HIGH AFFINITY MONOCLONAL ANTIBODY HEAVY AND LIGHT CHAIN PAIRS FROM HIGH THROUGHPUT SCREENS OF B-CELL AND HYBRIDOMA LIBRARIES | MERCK SHARP & DOHME CORP. (US) | 2022-02-03 | — | — | US | disclosed |
| US-11236169-B2 | Anti-DEspR monoclonal antibody targeted therapy and imaging for cancer and stroke | TRUSTEES OF BOSTON UNIVERSITY (US) | 2022-02-01 | — | — | US | disclosed |
| US-20220025042-A1 | ANTIBODIES SPECIFIC FOR IMMUNOGLOBULIN-LIKE TRANSCRIPT 3 (ILT3) AND USES THEREOF | MERCK SHARP & DOHME CORP. (US) | 2022-01-27 | — | — | US | disclosed |
| EP-3894863-A1 | IN VITRO METHOD FOR DETECTING AVIAN INTESTINAL DYSBIOSIS | Evonik Operations GmbH (DE) | 2021-10-20 | — | — | EP | disclosed |
| CN-113167803-A | In-vitro detection method for poultry intestinal dysbiosis | 赢创运营有限公司 | 2021-07-23 | — | — | CN | disclosed |
| WO-2020120376-A1 | IN VITRO METHOD FOR DETECTING AVIAN INTESTINAL DYSBIOSIS | EVONIK OPERATIONS GMBH (DE) | 2020-06-18 | — | — | WO | disclosed |
| EP-3478121-A1 | METHOD FOR SAMPLING GINGIVAL METABOLITES | The Procter and Gamble Company (US) | 2019-05-08 | — | — | EP | disclosed |
| US-10267797-B2 | Detection of oral microbial virulence factors | THE PROCTER & GAMBLE COMPANY (US) | 2019-04-23 | — | — | US | disclosed |
| US-10156566-B2 | Detoxification of microbial virulence factors in oral cavity | THE PROCTER & GAMBLE COMPANY (US) | 2018-12-18 | — | — | US | disclosed |
| US-9970934-B2 | Detection of oral microbial virulence factors | THE PROCTER & GAMBLE COMPANY (US) | 2018-05-15 | — | — | US | disclosed |
| US-9964472-B2 | Methods for sampling gingival metabolites | THE PROCTER & GAMBLE COMPANY (US) | 2018-05-08 | — | — | US | disclosed |
| EP-3292215-A1 | DETOXIFICATION OF MICROBIAL VIRULENCE FACTORS IN ORAL CAVITY | The Procter and Gamble Company (US) | 2018-03-14 | — | — | EP | disclosed |
| US-20180003598-A1 | METHODS FOR SAMPLING GINGIVAL METABOLITES | THE PROCTER & GAMBLE COMPANY | 2018-01-04 | — | — | US | disclosed |
| WO-2018005335-A1 | METHOD FOR SAMPLING GINGIVAL METABOLITES | THE PROCTER & GAMBLE COMPANY (US) | 2018-01-04 | — | — | WO | disclosed |
| US-20170119643-A1 | DETOXIFICATION OF MICROBIAL VIRULENCE FACTORS IN ORAL CAVITY | THE PROCTER & GAMBLE COMPANY | 2017-05-04 | — | — | US | disclosed |
| CN-106455664-A | Composition with high content of cyclic dipeptide | 三得利控股株式会社 | 2017-02-22 | — | — | CN | disclosed |
| CN-106456633-A | Sugar metabolism improving agent | 三得利控股株式会社 | 2017-02-22 | — | — | CN | disclosed |
| WO-2016179561-A1 | DETOXIFICATION OF MICROBIAL VIRULENCE FACTORS IN ORAL CAVITY | THE PROCTER & GAMBLE COMPANY (US) | 2016-11-10 | — | — | WO | disclosed |
| US-20160327557-A1 | DETECTION OF ORAL MICROBIAL VIRULENCE FACTORS | THE PROCTER & GAMBLE COMPANY | 2016-11-10 | — | — | US | disclosed |
| US-20140343865-A1 | Biomarkers for Kidney Cancer and Methods Using the Same | METABOLON, INC. | 2014-11-20 | — | — | US | disclosed |
| US-20140296134-A1 | METHODS AND USES FOR METABOLIC PROFILING FOR CLOSTRIDIUM DIFFICILE INFECTION | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-10-02 | — | — | US | disclosed |
| EP-2776829-A1 | METHODS AND USES FOR METABOLIC PROFILING FOR CLOSTRIDIUM DIFFICILE INFECTION | The Board of Regents of The University of Texas System (US) | 2014-09-17 | — | — | EP | disclosed |
| EP-2661266-A2 | CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES | Elcelyx Therapeutics, Inc. (US) | 2013-11-13 | — | — | EP | disclosed |
| WO-2013070962-A1 | METHODS AND USES FOR METABOLIC PROFILING FOR CLOSTRIDIUM DIFFICILE INFECTION | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2013-05-16 | — | — | WO | disclosed |
| WO-2012094636-A2 | CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES | ELCELYX THERAPEUTICS, INC. (US) | 2012-07-12 | — | — | WO | disclosed |
| US-7846902-B2 | Dipeptide-comprising composition for oral administration | KYOWA HAKKO BIO CO., LTD. (JP) | 2010-12-07 | — | — | US | disclosed |
| US-20100075017-A1 | SALTY TASTE ENHANCER, FOOD OR DRINK AND METHOD FOR PRODUCING FOOD OR DRINK | HIROSHIMA UNIVERSITY (JP) | 2010-03-25 | — | — | US | disclosed |
| US-20080305151-A1 | Dipeptide-Comprising Composition for Oral Administration | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2008-12-11 | — | — | US | disclosed |
| EP-1941896-A1 | DIPEPTIDE-CONTAINING COMPOSITION FOR ORAL ADMINISTRATION | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2008-07-09 | — | — | EP | disclosed |
| EP-0560989-B1 | ENTERAL PREPARATION FOR CANCER THERAPY | OTSUKA PHARMA CO LTD (JP) | 1999-09-01 | — | — | EP | disclosed |
| US-5658895-A | SPRAY DRIED POWDER FROM OIL IN WATER EMULSION COMPRISING FREE AMINO ACIDS NUTRIENTS | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 1997-08-19 | — | — | US | disclosed |
| EP-0560989-A1 | ENTERAL PREPARATION FOR CANCER THERAPY | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 1993-09-22 | — | — | EP | disclosed |
| US-4631270-A | THIOMETHYLENE REPLACEMENTS | RESEARCH CORPORATION (US) | 1986-12-23 | — | — | US | disclosed |
| US-4086136-A | Process for producing a peptide using a serine or thiol proteinase | (ZAIDANHOJIN) SAGAMI CHEMICAL RESEARCH CENTER (JA) | 1978-04-25 | — | — | US | disclosed |
| US-4086136-A | Process for producing a peptide using a serine or thiol proteinase | (ZAIDANHOJIN) SAGAMI CHEMICAL RESEARCH CENTER (JA) | 1978-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (33 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260132222-A1 | PROTEINS SPECIFIC FOR BAFF AND B7RP1 AND USES THEREOF | SSB, IGSF11, CD22 | NPY4R 672/4885NPY1R 134/4885NPY5R 736/4885 |
| US-11905270-B2 | Carboxylic acid aromatic amides as antagonists of bradykinin B1 receptor | BDKRB1, BDKRB2, HCAR1 | NPY4R 379/4885NPY1R 32/4885NPY5R 180/4885 |
| US-11608336-B2 | Prodrugs of fused-bicyclic C5aR antagonists | C5AR2, C5AR1, C3AR1 | NPY4R 996/4885NPY1R 583/4885NPY5R 453/4885 |
| US-12268675-B2 | Diaryl substituted 6,5-fused ring compounds as C5aR inhibitors | C5AR1, C5AR2, C3AR1 | NPY4R 1215/4885NPY1R 581/4885NPY5R 219/4885 |
| US-11807609-B2 | Deuterated compounds as immunomodulators | C3AR1, C5AR1, C5AR2 | NPY4R 329/4885NPY1R 282/4885NPY5R 316/4885 |
| US-20240108040-A1 | HIGH INTENSITY SWEETENERS | TAS2R40, TAS2R60, TAS1R1 | NPY4R 1026/4885NPY1R 920/4885NPY5R 1220/4885 |
| US-12023319-B2 | Carboxylic acid aromatic amides | DDC, PAH, NAT1 | NPY4R 1886/4885NPY1R 963/4885NPY5R 951/4885 |
| US-12152182-B2 | Polymer nanoparticles for afterglow molecular imaging | CD68, ALG1, MB | NPY4R 1843/4885NPY1R 767/4885NPY5R 2814/4885 |
| US-20230151002-A1 | 6-5 FUSED RINGS AS C5a INHIBITORS | C5AR1, C5AR2, C3AR1 | NPY4R 1300/4885NPY1R 963/4885NPY5R 287/4885 |
| US-11479553-B2 | 5-5 fused rings as C5a inhibitors | C5AR1, C5AR2, C3AR1 | NPY4R 1202/4885NPY1R 884/4885NPY5R 149/4885 |
| US-12600792-B2 | Monoclonal antibodies and methods of use | IGSF11, IGLV6-57, CDY1; CDY1B | NPY4R 1373/4885NPY1R 994/4885NPY5R 1987/4885 |
| US-20230086179-A1 | CARBOXYLIC ACID AROMATIC AMIDES | DDC, PAH, NAT1 | NPY4R 1886/4885NPY1R 963/4885NPY5R 951/4885 |
| US-11485737-B2 | Diaryl substituted 5,5-fused ring compounds as C5aR inhibitors | C5AR1, C5AR2, C3AR1 | NPY4R 1185/4885NPY1R 607/4885NPY5R 102/4885 |
| US-12545746-B2 | Anti-BCMA car antibodies, conjugates, and methods of use | CD47, RBM25, CD22 | NPY4R 2887/4885NPY1R 2050/4885NPY5R 1535/4885 |
| US-20250188154-A1 | CORONAVIRUS ANTIBODIES AND USES THEREOF | FCGR3B, IGLV6-57, ACE | NPY4R 3439/4885NPY1R 3642/4885NPY5R 3250/4885 |
| US-11773091-B2 | 6-5 fused rings as C5a inhibitors | C5AR1, C5AR2, C3AR1 | NPY4R 1300/4885NPY1R 963/4885NPY5R 287/4885 |
| US-12239630-B2 | Carboxylic acid aromatic amides as antagonists of bradykinin B1 receptor | BDKRB1, BDKRB2, HCAR1 | NPY4R 305/4885NPY1R 38/4885NPY5R 165/4885 |
| US-11357246-B2 | High intensity sweeteners | TAS2R40, TAS2R60, TAS1R1 | NPY4R 1026/4885NPY1R 920/4885NPY5R 1220/4885 |
| US-11845729-B2 | Processes and intermediates in the preparation of C5aR antagonists | C5AR1, C5AR2, C3AR1 | NPY4R 1144/4885NPY1R 1009/4885NPY5R 408/4885 |
| US-11384079-B2 | 6-5 fused rings as C5a inhibitors | C5AR1, C5AR2, C3AR1 | NPY4R 1300/4885NPY1R 963/4885NPY5R 287/4885 |
| US-20230115912-A1 | DIARYL SUBSTITUTED 6,5-FUSED RING COMPOUNDS AS C5aR INHIBITORS | C5AR1, C5AR2, C3AR1 | NPY4R 1215/4885NPY1R 581/4885NPY5R 219/4885 |
| US-20230102258-A1 | C5AR ANTAGONISTS | C5AR1, C5AR2, C3AR1 | NPY4R 896/4885NPY1R 743/4885NPY5R 414/4885 |
| US-20230043209-A1 | CARBOXYLIC ACID AROMATIC AMIDES | DDC, PAH, NAT1 | NPY4R 1886/4885NPY1R 963/4885NPY5R 951/4885 |
| US-20230008966-A1 | PROCESSES AND INTERMEDIATES IN THE PREPARATION OF C5aR ANTAGONISTS | C5AR1, C5AR2, C3AR1 | NPY4R 1144/4885NPY1R 1009/4885NPY5R 408/4885 |
| US-12622959-B2 | Coronavirus recombinant spike protein, polynucleotide encoding same, vector comprising polynucleotide, and vaccine for preventing or treating coronavirus infection, comprising vector | SARS1, TMPRSS2, CD4 | NPY4R 2923/4885NPY1R 1842/4885NPY5R 2496/4885 |
| US-20260041769-A1 | AGENTS AND METHODS FOR TARGETED DELIVERY OF NUCLEIC ACIDS TO CELLS | CD74, HAVCR2, PHOSPHO1 | NPY4R 919/4885NPY1R 2340/4885NPY5R 2488/4885 |
| US-20170119643-A1 | DETOXIFICATION OF MICROBIAL VIRULENCE FACTORS IN ORAL CAVITY | GSTM2, GSTA2, GSTA1 | NPY4R 4845/4885NPY1R 4873/4885NPY5R 4860/4885 |
| US-10156566-B2 | Detoxification of microbial virulence factors in oral cavity | GSTM2, GSTA2, GSTA1 | NPY4R 4845/4885NPY1R 4873/4885NPY5R 4860/4885 |
| US-20230271931-A1 | CARBOXYLIC ACID AROMATIC AMIDES AS ANTAGONISTS OF BRADYKININ B1 RECEPTOR | BDKRB1, BDKRB2, HCAR1 | NPY4R 305/4885NPY1R 38/4885NPY5R 165/4885 |
| US-11758933-B2 | High intensity sweeteners | TAS2R40, TAS2R60, TAS1R1 | NPY4R 1026/4885NPY1R 920/4885NPY5R 1220/4885 |
| US-20260014278-A1 | HYBRID PEPTIDE DENDRIMER SYSTEMS AND EXTRAHEPATIC DELIVERY | CD47, CD2BP2, CD40LG | NPY4R 771/4885NPY1R 1523/4885NPY5R 2806/4885 |
| US-11478460-B2 | Diaryl substituted 6,5-fused ring compounds as C5aR inhibitors | C5AR1, C5AR2, C3AR1 | NPY4R 1215/4885NPY1R 581/4885NPY5R 219/4885 |
| US-20260035480-A1 | SICKLED BETA GLOBIN ANTIBODIES | HBB, HBZ, HBG2 | NPY4R 3213/4885NPY1R 2995/4885NPY5R 3331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.